Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut bacterial Infection drives Parkinsonian pathology in LRRK2 G2019S Knock-in Mice.

bioRxiv : the preprint server for biology·2026
Same author

Loss of ASIC1A-dependent inhibitory neuron activity in basolateral amygdala is associated with increased CO <sub>2</sub> -evoked jumping.

bioRxiv : the preprint server for biology·2026
Same author

Distinct activity in prefrontal projections promotes temporal control of action.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Ventral tegmental area dopamine controls timing variability.

bioRxiv : the preprint server for biology·2025
Same author

Computational Properties of the Prefrontal Cortex.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2025
Same author

A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults.

Journal of Parkinson's disease·2025

Related Experiment Video

Updated: May 9, 2026

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
11:01

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease

Published on: August 30, 2011

Parkinson's and Alzheimer's disease impairs temporal precision.

Matthew A Weber1, Christopher M Hunter1, Nandakumar S Narayanan1

  • 1University of Iowa.

Research Square
|February 6, 2026
PubMed
Summary

Temporal precision, but not accuracy, is consistently impaired in Parkinson's and Alzheimer's disease. This finding highlights interval timing as a key cognitive assay for neurodegenerative disorders.

Keywords:
AccuracyAlzheimer’s diseaseInterval timingParkinson’s diseasePrecision

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Related Experiment Videos

Last Updated: May 9, 2026

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
11:01

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease

Published on: August 30, 2011

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Area of Science:

  • Neuroscience
  • Cognitive Psychology
  • Neurology

Background:

  • Neurodegenerative diseases like Parkinson's and Alzheimer's are associated with temporal processing deficits.
  • Interval timing paradigms assess the ability to estimate or produce time intervals, involving working memory and attention.
  • Key metrics for timing performance include temporal accuracy (mean estimate) and temporal precision (variability of estimates).

Purpose of the Study:

  • To conduct a meta-analysis examining temporal accuracy and precision in patients with Parkinson's disease and Alzheimer's disease.
  • To determine if temporal processing deficits are consistently observed across studies in these neurodegenerative conditions.

Main Methods:

  • Meta-analysis of 14 studies involving Parkinson's disease patients.
  • Meta-analysis of 10 studies involving Alzheimer's disease patients.
  • Examination of temporal accuracy and temporal precision as primary outcome measures.

Main Results:

  • Temporal precision was reliably impaired across studies in both Parkinson's disease and Alzheimer's disease.
  • Temporal accuracy was not consistently impaired in either disease.
  • Despite diverse methodologies, impaired temporal precision emerged as a consistent finding.

Conclusions:

  • Temporal precision is a robust indicator of cognitive dysfunction in Parkinson's and Alzheimer's disease.
  • Interval timing serves as a reliable assay for studying cognitive deficits in neurodegenerative diseases.
  • These findings may extend to other neurological and psychiatric disorders with cognitive impairments.